Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis